How safe are folic acid supplements?

Archives of Internal Medicine

Volumn 156, Issue 15, 1996, Pages 1638-1644

  Campbell, Norman R C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; COBALAMIN; FOLIC ACID; FOLINIC ACID; METHOTREXATE; ZINC;

ATHEROSCLEROSIS; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DIET SUPPLEMENTATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOLATE METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; MALARIA; MALIGNANT NEOPLASTIC DISEASE; NEURAL TUBE DEFECT; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM DISEASES; DRUG ANTAGONISM; FOLIC ACID; HUMANS; NEOPLASMS; VITAMIN B 12 DEFICIENCY; ZINC;

EID: 0029848516     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.15.1638     Document Type: Review

References (108)

1. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832-1835.
2. Kirke PN, Daly LE, Elwood JH. A randomized trial of low-dose folic acid to prevent neural tube defects: the Irish Vitamin Study Group. Arch Dis Child. 1992;67:1442-1446.
3. Laurence KM, James N, Millar MH, Tennant GB, Campbell H. Double-blind randomized controlled trial of folate treatment belore conception to prevent recurrence of neural-tube detects. BMJ. 1981;282:1509-1511.
4. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube detects with folic acid supplementation: Cuban experience. Prenat Diagn. 1990,10:149-152.
5. Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
6. Smithells RW, Sheppard S, Schorah CJ, et al. Apparent prevention of neural-tube defects by periconceptional vitamin supplementation. Arch Dis Child 1981;56:911-918.
7. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural-tube defects. MMWR Morb Mortal Wkly Rep. 1992;41(RR-14):1-7.
8. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
9. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994;236:603-617.
10. Mason JB. Folate status: effects on carcinogenesis. In: Bailey LB, ed. Folate in Health and Disease. New York, NY: Marcel Dekker Inc: 1995: 361-378.
11. Block G. Micronutrients and cancer: time for action? J Natl Cancer Inst. 1993;85:846-848.
12. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst. 1993; 85:875-884.
13. Butterworth CE, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA. 1992;267:528-533.
14. Hillman RS. Hematopoietic agents: growth factors, minerals, and vitamins. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. Elmsford. NY: Pergamon Press Inc: 1990;1277-1310.
15. Alhadeff L, Gualtieri CT. Lipton M. Toxic effects of water-soluble vitamins. Nutr Rev 1984; 42:33-40.
16. Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989; 50:353-358.
17. Department of Health and Human Services. Folic acid proposed rules. Federal Register. 1993; 58:53254-53316.
18. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906-908.
19. Savage DG, Lindenbaum J. Folate-cobalamin interactions. In: Bailey LB, ed. Folate in Health and Disease, New York, NY: Marcel Dekker Inc; 1995:237-285.
20. Mitchell DC, Vilter RW, Vilter CF. Hypersensitivity to folic acid. Ann Intern Med. 1949;31: 1102-1105.
21. Tamura T. Nutrient interaction of folate and zinc. In: Bailey LB, ed. Folate in Health and Disease. New York, NY: Marcel Dekker Inc; 1995:287-312.
22. Hunter R, Barnes J, Oakeley HF, Matthews DM. Toxicity of folic acid given in pharmacological doses to healthy volunteers. Lancet. 1970;1: 61-63.
23. Hellstrom L. Lack of toxicity of folic acid given in pharmacological doses to healthy volunteers. Lancet. 1971;1:59-61.
24. Richens A. Toxicity of folic acid. Lancet. 1971, 1:912.
25. Suarez RM, Spies TD, Suarez RM Jr. The use of folic acid in sprue. Ann Intern Med. 1947; 26:643-677.
26. Sheehy TW. Folic acid: lack of toxicity. Lancet. 1973:1:37.
27. Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr. Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug-treated epileptics. Am J Clin Nutr. 1975;28:51-58.
28. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33: 9-18.
29. Krogh CME, ed. Compendium of Pharmaceutical and Specialties. 29th ed, Ottawa, Ontario: Canadian Pharmaceutical Association; 1989: BL21-BL37.
30. Healton EB, Savage DG, Brust JCM, Garrett TJ, Lindenbaum J. Neurological aspects of cobalamin deficiency. Medicine (Baltimore). 1991,70: 229-245.
31. Borch K, Liedberg G. Prevalence and incidence of pernicious anemia. Scand J Gastroentrol. 1984;19:154-160.
32. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Sec. 1992;40:1197-1204.
33. 12 levels. Ann Intern Med. 1996; 124:299-304.
34. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318:1720-1728.
35. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency, I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 1990;34:90-98.
36. Chanarin I. The Megaloblastic Anaemias. 2nd ed. Oxford, England: The Alden Press; 1979: 317-318.
37. 12 levels in patients on anticonvulsants. Lancet. 1969; 2:666-667.
38. 12 concentration in pernicious anemia in relapse. J Clin Lab Med. 1958;51:667-671.
39. 12-folate interrelationships in megaloblastic anemia. Br J Haematol. 1966;12:283-296.
40. 12 and folic acid metabolism: folic acid clearance studies. J Clin Invest. 1962;41:1263-1276.
41. Baylis EM, Crowiey JM, Preece JM, Sylvester PE, Marks V. Influence of folic acid on blood-phenytoin levels. Lancet. 1971;1:62-64.
42. Norris JW, Pratt RF. A controlled study of folic acid in epilepsy. Neurology. 1971;21:659-664.
43. Bethell FH, Sturgis CC. The relation of therapy in pernicious anemia to changes in the nervous system: early and late results in a series of cases observed for a period of not less than 10 years and early results with folic acid. Blood. 1948;3:57-67.
44. Challenger WA, Korst DR. Pitfalls in the diagnosis and treatment of pernicious anemia. Am J Med Sci. 1960;134:226-231.
45. Hall BE, Watkins CH. Experience with pteroylglutamic (synthetic folic) acid in the treatment of pernicious anemia. J Lab Clin Med. 1947; 32:622-634.
46. Heinle RW, Welch AD. Folic acid in pernicious anemia: failure to prevent neurologic relapse. JAMA. 1947;133:739-741.
47. 12 deficiency. Arch Neurol. 1980;37: 590-592.
48. Schwartz SO, Kaplan SR, Armstrong BE. The long-term evaluation of folic acid in the treatment of pernicious anemia, J Lab Clin Med. 1950; 35:894-898.
49. Sinow RM, Johnson CS, Karnaze DS, Siegel ME, Carmel R. Unsuspected pernicious anemia in a patient with sickle cell disease receiving routine folate supplementation. Arch Intern Med. 1987;147:1828-1829.
50. Katz M. Potential danger of self-medication with folic acid. N Engl J Med. 1973;289:1095.
51. Folic acid and neural tube defects. Lancet. 1991; 2:153-154.
52. Marshall RA, Jandl JH. Responses to 'physiologic' doses of folic acid in the megaloblastic anemias. Arch Intern Med. 1960;105:352-360.
53. Chosy JJ, Clatanoff DV, Schilling RF. Responses to small doses of folic acid in pernicious anemia. Am J Clin Nutr. 1962;10:349-350.
54. 12 in megaloblastic anemias. Acta Med Scand. 1962;172:427-443.
55. Carmel R, Karnaze DS. Physician response to low serum cobalamin levels. Arch Intern Med. 1986;146:1161-1165.
56. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990;76:871-881.
57. Chanarin I, Malkowska V, O'Hea AM, Rinsler MG, Price AB. Megaloblastic anemia in a vegetarian Hindu community. Lancet. 1985;2:1168-1172.
58. 12 and folate levels in long-term vegans. Isr J Med Sci. 1990;26:309-312.
59. Zimran A, Hershko C. The changing pattern of megaloblastic anemia: megaloblastic anemia in Israel. Am J Clin Nutr. 1983;37:855-861.
60. Olney JW, Fuller TA, de Gubareff T, Labruyere J. Intrastriatal folic acid mimics the distant but not local brain-damaging properties of kainic acid. Neurosci Left. 1981;25:185-191.
61. Baxter MG, Millar AA, Webster RA. Some studies on the convulsant action of folic acid. Br J Pharmacol. 1973;48:350-351.
62. Weller M, Marini AM, Martin B, Paul SM. The reduced unsubstituted pteroate moiety is required for folate toxicity of cultured cerebellar granule neurons. J Pharmacol Exp Ther. 1994; 269:393-401.
63. McGeer PL, Zeldowicz L, McGeer EG. A clinical trial of folic acid in Parkinson's disease. Can Med Assoc J. 1972;106:145-146.
64. Furlanut M, Benetello P, Avogaro A, Dainese R. Effects of folic acid on phenytoin kinetics in healthy subjects. Clin Pharmacol Ther. 1978; 24:294-297.
65. Chanarin I, Laidlow J, Longbridge LW, Mollin DL. Megaloblastic anemia due to phenobarbitone: the convulsant action of therapeutic doses of folic acid. BMJ. 1960;1:1099-1102.
66. Strauss RG, Bernstein R. Folic acid and Dilantin antagonism in pregnancy. Obstet Gynecol. 1974;44:345-348.
67. Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD. Phenytoin and folic acid: individualized drug-drug interactions. Ther Drug Monit. 1983;5:395-399.
68. Inoue F, Kolabinski I. Possible interaction between phenytoin therapy and folate supplement: 2 case reports. Can J Hosp Pharm. 1986; 39:16.
69. Reynolds EH, Wales MB. Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients. Lancet. 1967;1:1086-1088.
70. Gibberd FB, Nicholls A, Wright MG. The influence of folic acid on the frequency of epileptic attacks. Eur J Clin Pharmacol. 1981;19:57-60.
71. Mattson RH, Gallagher BB, Reynolds EH, Glass D. Folate therapy in epilepsy. Arch Neurol. 1973; 29:78-81.
72. Ralston AJ, Snaith RP, Hinley JB. Effects of folic acid on fit-frequency and behaviour in epileptics on anticonvulsants. Lancet 1970;1:867-868.
73. Horwitz FA, Klipstein FK, Lovelace RE. Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant therapy. Lancet. 1968;1:563-565.
74. Backman N, Holm AK, Hanstrom L, Blomquist HK, Heijbel J, Safstrom G. Folate treatment of diphenylhydantoin-induced gingival hyperplasia. Scand J Dent Res. 1989;97:222-232.
75. Jersen ON, Olesen OV. Subnormal serum folate due to anticonvulsive therapy. Arch Neurol. 1970;22:181-183.
76. Brown RS, Di Stanislao PT, Beaver WT, Bottomley WK. The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia: a double-blind, randomized, placebo-controlled, parallel study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1991;71:565-568.
77. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913-914.
78. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of meumatoid arthritis: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795-803.
79. Weinblatt ME, Maier AL, Coblyn JS. Low-dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week randomized placebo controlled trial. J Rheumatol. 1993;20:950-952.
80. Jolivet J. Biochemical and pharmacologic rationale for high-dose methotrexate. Monogr Natl Cancer Inst 1987;5:61-65.
81. Cohen P, Dix D. On the role of folate deficiency in cancer therapy. Clin Chem. 1988;34: 1945-1946.
82. Schroder H, Clausen N, Ostergard E, Pressler T. Folic acid supplements in vitamin tablets: a determinant of haematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1986;3:241-247.
83. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833-841.
84. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28:466-469.
85. Tong MJ, Strickland GT, Votteri BA, Gunning JJ. Supplemental folates in the therapy of Plasmodium falciparum malaria. JAMA. 1970;214: 2330-2333.
86. Milne DB, Canfield WK, Mahalko JR, Sandstead HH. Effect of oral folic acid supplements on zinc, copper, and iron absorption and excretion. Am J Clin Nutr. 1984;39:535-539.
87. Simmer K, Iles CA, James C, Thompson RP. Are iron-folate supplements harmful? Am J Clin Nutr. 1987;45:122-125.
88. Fuller NJ, Bates CJ, Evans PH, Lucas A. High tolate intakes related to zinc status in preterm infants. Eur J. Pediatr. 1992;151:51-53.
89. Mukhurjee MD, Sandstead HH, Ratnaparkhi MV, Johnson LK, Milne DB, Stelling HP. Maternal zinc, Iron, folic acid and protein nutriture and outcome of human pregnancy. Am J Clin Nutr. 1984;40:496-507.
90. Hambidge M, Hackshaw A, Wald N. Neural tube defects and serum zinc. Br J Obstet Gynecol. 1993;100:746-749.
91. Butterworth CE Jr, Hatch K, Cole P, et al. Zinc concentration in plasma and erythrocytes of subjects receiving folic acid supplementation. Am J Clin Nutr. 1988;47:484-486.
92. Tamura T, Goldenberg RL, Freeberg LE, Cliver SP, Cutter GR, Hoffman HJ. Maternal serum folate and zinc concentrations and their relationships to pregnancy outcome. Am J Clin Nutr. 1992;56:365-370.
93. Arnaud J, Favier A, Herrmann MA, Pilorget JJ. Effect of folic acid and folinic acid on zinc absorption. Ann Nutr Metab. 1992;36:157-161.
94. Keating JN, Wada L, Stokstad ELR, King JC. Folic acid: effect on zinc absorption in humans and in the rat. Am J Clin Nutr. 1987;46:835-839.
95. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49:5736-5747.
96. 12. JAMA. 1988;259:1525-1530.
97. Herbert V. Folate supplements should be appropriately labeled to protect consumers. Pediatrics. 1994;93:694-695.
98. Herbert V. Folate deficiency to protect against malaria. N Engl J Med. 1993;328:1127.
99. Sesin GP, Kirschenbaum H. Folic acid hypersensitivity and lever: a case report. Am J Hosp Pharm. 1979;36:1565-1567.
100. Sparling R, Abela M. Hypersensitivity to folic acid therapy. Clin Lab Haematol. 1985;7:184-185.
101. Gotz VP, Lauper RD. Folic acid hypersensitivity or tartrazine allergy? Am J Hosp Pharm. 1980; 37:1470-1474.
102. Woodliff HJ, Davis RE. Allergy to folic acid. Med J Aust. 1966;1:351-352.
103. Mathur BP. Sensitivity of folic acid: a case report. Indian J Med Sci. 1966;20:133-134.
104. Sesin GP, Kirschenbaum H. Folic acid hypersensitivity or tartrazine allergy? Am J Hosp Pharm. 1980;37:1474.
105. Chanarin I. Folate and cobalamin. Clin Haematol. 1985;14:629-641.
106. 6 occur commonly in elderly people. Am J Clin Nutr. 1993; 58:468-476.
107. Marcus DL, Freeman ML. Folic acid deficiency in the elderly. J Am Geriatr Soc. 1985;33:552-558.
108. Jukes TH. Tom Douglas Spies. J Nutr. 1972; 102:1395-1399.